Riccardo Corigli

Title: Riccardo Corigli: Innovator in Matrix Metalloproteinase Inhibitors

Introduction

Riccardo Corigli is a notable inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of matrix metalloproteinase inhibitors. With a total of 2 patents to his name, Corigli's work is pivotal in addressing various medical conditions.

Latest Patents

His latest patents focus on matrix metalloproteinase inhibitors, specifically a compound that is an amine derivative of a specific formula. This compound is designed to inhibit matrix metalloproteinases (MMPs) and the release of tumor necrosis factor-alpha (TNF) from cells. These inhibitors are particularly useful in the prevention, control, and treatment of diseases where MMPs or TNF are involved, especially in tumoral and inflammatory diseases. The patents also describe processes for their preparation and pharmaceutical compositions containing them.

Career Highlights

Corigli is associated with Pharmacia & Upjohn S.p.a., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing treatments that target critical pathways in disease progression.

Collaborations

Throughout his career, Corigli has collaborated with notable colleagues, including Marco Alpegiani and Daniela Jabes. These partnerships have enhanced the research and development of his innovative solutions.

Conclusion

Riccardo Corigli's contributions to the field of pharmaceuticals, particularly through his patents on matrix metalloproteinase inhibitors, highlight his role as a key innovator. His work continues to impact the treatment of significant medical conditions.